Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Trial Profile

Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Blinatumomab (Primary) ; Asparaginase; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Etoposide; Folinic acid; Folinic acid; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Mitoxantrone; Pegaspargase; Tioguanine; Vincristine
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 Planned primary completion date changed from 3 Apr 2018 to 31 Mar 2022.
    • 01 Jun 2015 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
    • 08 Mar 2015 Status changed from recruiting to suspended, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top